Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...

The study met its main goal, but those watching closely had hoped for an average result of at least 25% weight loss.

The FDA has followed its usual procedure of wrapping up a series of new drug approvals as the year draws to a close, with ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

FDA approves Hikma Pharmaceuticals' generic version of Victoza, a once-daily GLP-1 injection for Type 2 diabetes. Other drugmakers also entering the market.

Ozempic was manufactured and approved by the United States’ Food and Drug Administration seven years ago (2017). This drug ...

The House Ethics Committee’s bombshell report on former Rep. Matt Gaetz’s ethical conduct found that Gaetz violated Florida ...